modernretina3 日
Exegenesis Bio provides an update on EXG102 and EXG202 for wet AMD
EXG102 and EXG202 are investigational gene therapy candidates for wet age-related macular degeneration that are in ...
modernretina6 日
Retinopathy associated with hair dye
Researchers described the presence of multiple bilateral serous retinal detachments (SRDs) found in 3 women after they used ...
modernretina11 日
More than 300 patients randomized in the SOL-1 Phase 3 trial for OTX-TKI
More than 300 patients have been randomized in the SOL-1 Phase 3 trial for OTX-TKI (AXPAXLI, axitinib intravitreal implant).
modernretina6 日
Study suggests visual system affected in patients with mild traumatic brain injury
It is noteworthy that patients with mild TBI often report visual issues despite normal results of visual acuity measurements ...
modernretina7 日
Study: CRVO patients face higher heart attack risk
The authors searched PubMed, Scopus, MEDLINE, ScienceDirect, and ClinicalTrials.gov, and selected studies based on reports ...
modernretina5 日
Beacon Therapeutics announces positive 3-month data from Phase 2 DAWN trial of AGTC-501 in ...
Beacon Therapeutics presented 3-month interim safety and efficacy data from the Phase 2 DAWN trial of laru-zova (AGTC-501) for X-linked retinitis pigmentosa (XLRP) at the FLORetina ICOOR 2024 meeting ...